Regeneron Pharmaceuticals Inc
REGNView Detailed Chart
557.910USD
-13.149-2.30%
Close 04/15, 16:00（ET）Quotes delayed by 15 min
61.15BMarket Cap
13.86P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.30%
5 Days
+0.19%
1 Month
-16.33%
6 Months
-45.11%
Year to Date
-21.67%
1 Year
-37.91%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
28
analysts
BUY
Current Rating
909.084
Target Price
59.19%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
558
Total
5
Median
6
Average
Company name
Ratings
Analysts
Regeneron Pharmaceuticals Inc
REGN
28
CRISPR Therapeutics AG
CRSP
29
Intellia Therapeutics Inc
NTLA
28
Moderna Inc
MRNA
27
Exact Sciences Corp
EXAS
27
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
112
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Indicators
Indicators
Value
Direction
MACD(12,26,9)
-7.645
Sell
RSI(14)
33.708
Neutral
STOCH(KDJ)(9,3,3)
32.525
Neutral
ATR(14)
28.050
High Vlolatility
CCI(14)
-62.063
Neutral
Williams %R
72.820
Sell
TRIX(12,20)
-0.791
Sell
StochRSI(14)
72.818
Sell
Moving Average
Indicators
Value
Direction
MA5
561.178
Sell
MA10
574.517
Sell
MA20
609.917
Sell
MA50
660.314
Sell
MA100
690.967
Sell
MA200
868.082
Sell
News
More news coming soon, stay tuned...
Company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company codeREGN
CompanyRegeneron Pharmaceuticals Inc
CEODr. Leonard S. Schleifer, M.D., Ph.D
Websitehttps://www.regeneron.com/
